Engineered safety in cell therapy
AssigneesInnovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.
InventorsChengfei Pu, Zhiyuan Cao, Zhao Wu, Lei Xiao
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compositions and methods for treating cancer. For example, a modified cell may include a polynucleotide comprising an NFAT promoter, a nucleotide sequence encoding therapeutic agent, and a nucleotide sequence encoding a VHL-interaction domain of HIF1α, wherein the therapeutic agent comprises, for example, IL-12, IL-6, and/or IFNγ.
Claims20
A method for modifying a population of immune cells, the method comprising:
- contacting the population of immunocytes with a mixture of lentiviral vectors, thereby obtaining the modified immunocytes, wherein the mixture of lentiviral vectors comprises:
- a first vector encoding a CAR targeting a solid tumor antigen;
- a second vector encoding a CAR targeting a white blood cell antigen and IL6;
- a third lentiviral vector encoding a CAR targeting the white blood cell antigen and IFNγ;
- and
- a fourth lentiviral vector encoding a CAR targeting the white blood cell antigen and IL12.
A mixture of lentiviral vectors for modifying a population of immunocytes to express chimeric antigen receptors (CARs), wherein the mixture comprises:
- a first lentiviral vector encoding a CAR targeting a solid tumor antigen;
- a second lentiviral vector encoding a CAR targeting a white blood cell antigen and IL6;
- a third lentiviral vector encoding a CAR targeting a white blood cell antigen and IFNγ;
- and
- a fourth lentiviral vector encoding a CAR targeting a white blood cell antigen and IL12.
Dependencies are inferred from the claim text.